Myomo, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Myomo, Inc. is a wearable medical robotics company specializing in the design, development, and production of myoelectric orthotic devices primarily aimed at improving arm and hand function for individuals affected by neurological disorders and upper-limb paralysis. Its core product is the MyoPro® powered upper-limb orthosis, a lightweight, non-invasive brace that restores motor functions in paralyzed or weakened arms by sensing the user’s own neurological signals through surface myoelectric sensors. The MyoPro product line serves patients with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, cerebral palsy, and other neuromuscular diseases or injuries. The company’s products enable users to regain arm and hand functionality to perform daily activities independently, thereby reducing long-term care costs. Myomo’s technology was originally developed through proprietary research at MIT and Harvard Medical School. The company operates internationally with key markets in the United States and Germany, targeting healthcare providers, orthotics and prosthetics professionals, and patients with neuromuscular impairments. Founded in 2004, Myomo is headquartered in Burlington, Massachusetts. Recent developments include a notable increase in revenues demonstrated by a 23% year-over-year growth in 2025 with Q3 revenues reaching $10.1 million, marking the strongest quarter of the year in authorizations and orders driven by both U.S. and international orthotics and prosthetics channels. Myomo’s strategic focus on expanding recurring patient sources via its U.S. and international O&P providers and its MyoConnect offering has gained traction. The company initiated several manufacturing cost reduction projects expected to improve gross margins starting in late 2026. Despite a dip in gross margin to 63.8% in Q3 2025 due to lower average selling prices and higher material and payroll costs, operational efficiencies and cost management have been a priority. Myomo also secured a $12.5 million funding loan to support its growth initiatives and maintain liquidity. Key management, including CEO Paul R. Gudonis, has reinforced commitments towards scaling operations, increasing financial sustainability, and supporting international expansion. Additionally, insider stock purchases by company directors underscore confidence in the company’s strategic path and growth prospects. Overall, Myomo operates within the healthcare equipment industry, focusing on advanced medical robotics in upper-limb orthotics with an emphasis on neuromuscular and neurological injury rehabilitation, serving patients globally through medical device innovation and strategic partnerships. This description integrates the company’s core products, operational activities, strategic changes, financial trends, founding information, and market presence.
Company News
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Myomo Q2 Earnings Call Highlights
Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo Reports Second Quarter 2026 Financial and Operating Results
Myomo to Report Second Quarter 2026 Financial Results on August 5
Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock
Myomo Appoints Joseph M. Manko to its Board of Directors
Here Is Why Bargain Hunters Would Love Fast-paced Mover Myomo (MYO)
Myomo, Inc. (MYO) Q1 2026 Earnings Call Transcript
Myomo, Inc. (MYO) Reports Q1 Loss, Beats Revenue Estimates
Myomo Reports First Quarter 2026 Financial and Operating Results
Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.
Myomo to Report First Quarter 2026 Financial Results on May 7
Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
Myomo Appoints William J Febbo to its Board of Directors
Myomo, Inc. (MYO) Q4 2025 Earnings Call Transcript
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates